| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |